U.S. Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.07-0.05 (-0.82%)
At close: 4:00PM EDT

6.14 +0.07 (1.16%)
After hours: 4:12PM EDT

People also watch
SGENIMMUEXELINCYCLDX
  • A
    Abraham
    Abraham

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • B
    BobDole
    BobDole
    Hmmm not sure what to say about this stock right now. The 1 month chart shows lower lows, lower highs. That's usually a bearish move.
  • T
    Tony
    Tony

    MicroCap News Alert: - Startup - Clean Energy Technologies (CETY) buys General Electric “Heat Recovery Systems Division” and within 2 years achieves break-even with sales now set to soar and to be profitable.

    CETY announced today the launch of Pacific Rim Initiative with over 20 locations already identified by CETY and PPA power company authorities.

    Early orders likely to exceed $25 million in annuitized sales. 12 month target price $.25

    CETY/GE proprietary oil-free magnetic levitation turbine technology shatters the competition’s old oil-lubricated screw expander technologies.

    Company expects to up list to NASDAQ.

    CETY's implementation includes creative lease financing structure, that facilitates rapid adoption and ease of entry with long-term payment structure that allows the utility user to align its investment with actual energy and cost savings realized through use of Clean Cycle™ units," said Kam Mahdi, CEO of CETY.

    CETY being welcomed with red carpet to largest markets in the world in need of clean energy.

    https://finance.yahoo.com/news/clean-energy-technologies-cety-launches-131500960.html

    Clean Energy Technologies (CETY) Launches Pacific Rim Initiative
    COSTA MESA, Calif. , Aug. 15, 2017 Clean Energy Technologies, Inc. (OTC: CETY) announced that CETY officially launched its new campaign to deliver its energy solutions to Island Nations utilities at the ...
    finance.yahoo.com
  • B
    BobDole
    BobDole
    Uptrend appears unbroken. Stock didn't want to stay down yesterday.
  • J
    John D
    John D
    Why is it that most reports about this company are slanted to the negative? Why don't they tout the 6 company owned products and the 16 partnerships?
    One article stated that they had missed their projections three quarters in a row-fakenews?????

    John D
  • J
    Jarad
    Jarad

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • M
    Max
    Max
    Time to sell above 6! This stock is likely to end up flat again today, unable to hold any gains.
  • j
    jim
    jim
    Any scientists here? Anyone agrees with their notion that CD33 is not the reason for SGEN's failure?
  • B
    BobDole
    BobDole
    Sold at 6.11, rebought at 5.82. WEEE!!!!!!
  • B
    BobDole
    BobDole
    I think we'll see $6+ today. 5% increase gets us to $6.11. I think we might settle around $6.05 today (slightly under 4%)
  • A
    Alexis
    Alexis
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on IMGN before rallying up. the other week awe*some*sto-cks alerted this company i think. google them .
  • B
    BobDole
    BobDole
    Too early to shout "HEEIIILL YEAH!" ?
  • B
    BobDole
    BobDole

    Reiterate buy from Jefferies.
    http://www.analystratings.com/articles/jefferies-reaffirms-their-buy-rating-on-immunogen/

    Per https://www.tipranks.com/analysts/top the top 25 analysts are usually from Jefferies and RBC Capital.

    Jefferies Reaffirms Their Buy Rating on ImmunoGen - Analyst Ratings
    August 7, 2017 Jefferies analyst Michael Yee reiterated a Buy rating on ImmunoGen (NASDAQ: IMGN) yesterday and set a price target of $9. The company's shares closed on Fr
    www.analystratings.com
  • M
    Mike
    Mike
    I am betting this stock won't make it to years end without being bought out. This company has many drugs in various places in the pipeline, it is absolutely a buyout target, and buying with these short attacks is almost too easy, your about to watch this run in my opinion, either way short or long GLTA
  • B
    BobDole
    BobDole

    American Bulls confirmed buy on 8/7
    https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=IMGN

    Error Page
    Errorpage
    www.americanbulls.com
  • B
    BobDole
    BobDole
    Thanks for the cheap shares, whoever's manipulating this stock. Bought in high 5s, rode it to mid 7s and sold. Back for more. Suckas! Gotta have balls to play with the big boys.
  • G
    Good
    Good
    I have not seen a pipeline like this for another company with this size of market cap. This will fly and fly high. Hang in there, buy more on dips.
  • B
    BobDole
    BobDole

    This may be why a lot of biotech stocks are shooting up today. It's even better when the stock's been manipulated a lot since shorts now are panicking to cover.
    http://www.marketwatch.com/story/united-therapeutics-corp-stock-surges-9-on-report-of-possible-bids-for-company-2017-08-04-8914713

    United Therapeutics Corp. stock surges 9% on report of possible bids for company
    www.marketwatch.com
  • T
    Trinity
    Trinity
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on IMGN before rallying up. Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from Awe.Some.Sto-ck.s.
  • J
    JJ
    JJ
    no worries. this is going 12 at least this year.